Baidu
map

2020年EAN:AJOVY(fremanezumab)治疗难治性偏头痛安全有效

2020-05-26 Allan MedSci原创

偏头痛会造成严重的疾病和经济负担。

Teva制药公司在2020年欧洲神经病学学会(EAN)虚拟大会上介绍了AJOVY®(fremanezumab)治疗偏头痛的重要数据。fremanezumab数据包括对FOCUS试验、HALO发作性偏头痛(EM)试验和HALO慢性偏头痛(CM)试验的汇总分析。结果表明,与安慰剂相比,fremanezumab组患者在12周时的头痛较基线显著降低。

偏头痛会造成严重的疾病和经济负担。全球有超过10亿人受到影响,美国和欧盟每年因该疾病造成的损失达2000亿美元。偏头痛的病因被认为是环境因素和遗传因素的综合作用所致。大约三分之二的病例都有遗传因素的原因。激素水平的波动也可能是一个因素:在青春期之前,受到偏头痛影响的男童比女童要稍多,但在此之后,受到偏头痛影响的女性则比男性要多出两至三倍。偏头痛的准确致病原理目前尚不得而知,但普遍认为这是因为神经血管紊乱所导致的。

 

原始出处:

https://www.firstwordpharma.com/node/1726956?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-07-01 longerg
  2. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-07-12 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-07-04 tongyongming
  5. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-05-28 fengyi812
  7. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-05-28 freve
  8. [GetPortalCommentsPageByObjectIdResponse(id=1704827, encodeId=c74d1e048272e, content=<a href='/topic/show?id=7b952225aa' target=_blank style='color:#2F92EE;'>#Ajovy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2225, encryptionId=7b952225aa, topicName=Ajovy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d65d30842306, createdName=longerg, createdTime=Wed Jul 01 03:04:02 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912369, encodeId=8d2619123698a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jul 12 11:04:02 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010811, encodeId=792b2010811ce, content=<a href='/topic/show?id=68109860857' target=_blank style='color:#2F92EE;'>#难治性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98608, encryptionId=68109860857, topicName=难治性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Mar 16 12:04:02 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752281, encodeId=4a321e5228113, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Sat Jul 04 05:04:02 CST 2020, time=2020-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947948, encodeId=8f25194e948bb, content=<a href='/topic/show?id=ed66e66020' target=_blank style='color:#2F92EE;'>#Fremanezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7660, encryptionId=ed66e66020, topicName=Fremanezumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 16 21:04:02 CST 2020, time=2020-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528661, encodeId=db76152866153, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Thu May 28 01:04:02 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600582, encodeId=212d600582d8, content=👏👏, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/5924e86cc73c43efb5bad9dd92ac0d7b/63609a5527c447f48b59b39dd248a66f.jpg, createdBy=cf0a5102349, createdName=站在塔尖, createdTime=Tue May 26 14:50:35 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-05-26 站在塔尖

    👏👏

    0

相关资讯

曲坦类药物加NSAID联合治疗难治性偏头痛

科罗拉多大学的Chantal O’Brien博士在由该校主办的一场内科学会议上报告称,对于曲坦类单药治疗无效的急性偏头痛发作,合理的联合治疗常常是正确选择。关键是要确定能同时作用于头痛相关性中枢和外周通路的联合治疗方案。如果能够找到这样的方案,就能中止头痛并降低短期复发率。 一种曲坦类药物加一种非甾体抗炎药(NSAID),必要时再加一种止呕药物,就是一个合理的联合用药方案。在近年来的多项随机研究

拓展阅读

PLAST RECONSTR SURG:慢性和发作性偏头痛的非药物治疗: 系统综述和荟萃分析

偏头痛手术是一种具有成本效益的长期治疗方法,可减少头痛的频率、严重程度和持续时间,且无明显并发症风险。

J Headache Pain:单脉冲经颅磁刺激可有效预防性治疗难治性偏头痛

sTMS可能是一种长期预防难治性CM和HFEM的有效、耐受性良好的治疗选择。

J Headache Pain:单脉冲经颅磁刺激预防性治疗难治性偏头痛

这项开放标签分析表明,sTMS可能是一种长期预防难治性CM和HFEM有效、耐受性良好的治疗选择。

曲坦类药物加NSAID联合治疗难治性偏头痛

科罗拉多大学的Chantal O’Brien博士在由该校主办的一场内科学会议上报告称,对于曲坦类单药治疗无效的急性偏头痛发作,合理的联合治疗常常是正确选择。关键是要确定能同时作用于头痛相关性中枢和外周通路的联合治疗方案。如果能够找到这样的方案,就能中止头痛并降低短期复发率。 一种曲坦类药物加一种非甾体抗炎药(NSAID),必要时再加一种止呕药物,就是一个合理的联合用药方案。在近年来的多项随机研究

Baidu
map
Baidu
map
Baidu
map